Results for
"[search-keyword]"
Sponsor content
173 result(s) found, displaying 11 to 20
-
Australian Public Assessment Report (AusPAR)Opdualag (Nivolumab and Relatlimab) has been approved for the treatment of patients with unresectable or metastatic melanoma who are at least 12 years old.
-
Jan-2024Prescription medicine evaluationActive ingredient: nivolumab.
-
Australian Public Assessment Report (AusPAR)AusPAR for Sotyktu (deucravacitinib) for treatment of adult patients with moderate-to-severe plaque psoriasis.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOTYKTU deucravacitinib 6 mg film-coated tablet blister pack.
-
Australian Public Assessment Report (AusPAR)AusPAR for Camzyos (mavacamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OPDUALAG nivolumab 240mg and relatlimab 80mg in 20mL concentrate solution for IV infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAMZYOS mavacamten 5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAMZYOS mavacamten 2.5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAMZYOS mavacamten 10 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAMZYOS mavacamten 15 mg capsule blister pack.